3月31日 - ** 生物技术公司ImmunicIMUX.O股价盘前上涨5%至1.08美元
** 该公司称已任命康格尔顿（Jon Congleton）为董事会成员；他曾帮助梯瓦公司在美国推出多发性硬化症药物Copaxone
** 康格尔顿还担任过Mineralys Therapeutics、Impel NeuroPharma和Nivalis Therapeutics的首席执行官。
** 补充说公司正在开发一种治疗复发性多发性硬化症的口服实验药物 vidofludimus calcium，这种疾病会反复发作
** 该公司表示，该药物的后期研究结果预计将于 2026 年底公布
** 多发性硬化症是一种免疫系统攻击神经的疾病，会导致运动和视力问题
** 2025 年股价下跌约 47%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.